ArticleAsia-Pacific journal of ophthalmology (Philadelphia, Pa.)
The War on Diabetic Retinopathy: Where Are We Now?
Article in Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- The cross-sectional and longitudinal relationship of diabetic retinopathy to cognitive impairment: a systematic review and meta-analysis.Eye (London, England) · 2023Pooled it
- Diagnostic accuracy of teleretinal screening for detection of diabetic retinopathy and age-related macular degeneration: a systematic review and meta-analysis.BMJ open ophthalmology · 2022Pooled it
- Using artificial intelligence-assisted retinal imaging devices operated by non-specialist workers in detecting diabetic retinopathy in Sri Lanka.BMC global and public health · 2026Article
- Using OCT Angiography to Predict Diabetic Retinopathy Progression and Vision Decline in a Multiethnic Cohort.Ophthalmology science · 2026Article
- The Evolving Role of Anti-VEGF Therapy in Proliferative Diabetic Retinopathy: Evidence, Challenges, and Future Directions.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Development and Novel Therapeutics in Diabetic Retinopathy.Current diabetes reviews · 2026Review
- Precision Medicine in Diabetic Retinopathy: The Role of Genetic and Epigenetic Biomarkers.Journal of clinical medicine · 2025Review
- Diabetic retinopathy screening model in low and middle-income countries: a scoping review.BMC public health · 2025Article
- Advanced 3D retinal lesion segmentation using channel-spatial attention-guided multi-scale feature aggregation.Biomedical optics express · 2025Article
- Development and Validation of a Machine Learning Algorithm for Predicting Diabetes Retinopathy in Patients With Type 2 Diabetes: Algorithm Development Study.JMIR medical informatics · 2025Article
- The association between peripheral blood inflammatory markers and anti-VEGF treatment response in patients with type 2 diabetic macular edema.Frontiers in medicine · 2025Article
- Narrative review of comprehensive management strategies for diabetic retinopathy: interdisciplinary approaches and future perspectives.BMJ public health · 2025Review
- DDLA: a double deep latent autoencoder for diabetic retinopathy diagnose based on continuous glucose sensors.Medical & biological engineering & computing · 2024Article
- Cost-effectiveness of incorporating self-imaging optical coherence tomography into fundus photography-based diabetic retinopathy screening.NPJ digital medicine · 2024Article
- Ocular microvascular complications in diabetic retinopathy: insights from machine learning.BMJ open diabetes research & care · 2024Article
- Intravitreal conbercept injection with panretinal photocoagulation for high-risk proliferative diabetic retinopathy with vitreous hemorrhage.International journal of ophthalmology · 2024Article
- Effect of a self-care promoting program on engagement in self-care behaviors and health-related outcomes among persons with type 2 diabetes and diabetic retinopathy: A single-blind randomized controlled trial.Belitung nursing journal · 2024Article
- Article
- Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial.Frontiers in endocrinology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR), a major cause of blindness in working-age adults, is emerging as a major public health issue worldwide, in particular in low- and middle-income countries (LMIC). Traditionally, the management of DR has been on tertiary-level treatment (eg, laser, anti-VEGF injections and surgery) in specialized settings by highly trained ophthalmologists on individual patients. To win the war on DR, a paradigm shift in strategic focus and resources must be made from such tertiary treatment toward primary and secondary prevention, which are broader, more impactful, and cost-effective for the larger population. These include improving education and awareness of risk of DR among people initially diagnosed with diabetes, promoting behavioral modifications such as physical activity and medication adherence for improving glycemic and blood pressure control, setting up systematic screening programs for DR to detect the onset or progression of the disease, and implementing cost-effective, evidence-based policies and guidelines for managing DR. Additionally, there is a need to leverage on novel technology including the application of digital big data to predict people at risk of diabetes and DR, the use of wearable devices and smart phone apps, behavioral techniques including social media for self-management of diabetes, and telemedicine-based DR screening incorporating artificial intelligence (AI) to broaden access to screening in all settings. To turn the tide on the war on DR, we must reframe DR not only as a specific condition that can be managed by ophthalmologists, but fundamentally, as a preventable condition by shifting the weight of strategies from tertiary to secondary and primary battlegrounds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.